PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Michael Schmertzler Sells 2,500 Shares

Posted by George Bondi on Oct 9th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) Director Michael Schmertzler sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $63.39, for a total value of $158,475.00. Following the transaction, the director owned 1,294,094 shares in the company, valued at $82,032,618.66. This trade represents a 0.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Schmertzler also recently made the following trade(s):

On Wednesday, September 16th, Michael Schmertzler sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $67.12, for a total transaction of $671,200.00.
On Wednesday, September 9th, Michael Schmertzler sold 10,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $67.84, for a total transaction of $678,400.00.
On Wednesday, August 26th, Michael Schmertzler sold 12,500 shares of PTC Therapeutics stock. The stock was sold at an average price of $72.94, for a total transaction of $911,750.00.
On Wednesday, August 19th, Michael Schmertzler sold 12,500 shares of PTC Therapeutics stock. The shares were sold at an average price of $73.32, for a total transaction of $916,500.00.

PTC Therapeutics Stock Performance

Shares of PTCT stock traded up $2.14 on Friday, reaching $64.70. 1,171,186 shares of the company were exchanged, compared to its average volume of 1,374,659. The company has a market cap of $5.40 billion, a price-to-earnings ratio of -111.55, a P/E/G ratio of 1.95 and a beta of 0.49. The business has a 50-day moving average price of $68.43 and a 200 day moving average price of $71.98. PTC Therapeutics, Inc. has a 1 year low of $61.23 and a 1 year high of $90.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.68. The company had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. The firm’s revenue for the quarter was up 101.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.83) EPS. As a group, equities analysts anticipate that PTC Therapeutics, Inc. will post 1.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP acquired a new stake in shares of PTC Therapeutics in the second quarter valued at approximately $67,000. EverSource Wealth Advisors LLC raised its holdings in shares of PTC Therapeutics by 16.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 151 shares during the period. Harbor Investment Advisory LLC acquired a new position in shares of PTC Therapeutics during the 2nd quarter valued at about $81,000. Quantbot Technologies LP purchased a new stake in shares of PTC Therapeutics in the second quarter valued at about $112,000. Finally, GAMMA Investing LLC increased its position in PTC Therapeutics by 58.1% during the second quarter. GAMMA Investing LLC now owns 1,453 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 534 shares during the last quarter.

Wall Street Analysts Forecast Growth

PTCT has been the topic of several research reports. Royal Bank Of Canada decreased their target price on PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Cantor Fitzgerald increased their price objective on PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research note on Tuesday, September 22nd. Morgan Stanley raised their price objective on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Wall Street Zen raised shares of PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 19th. Finally, Wells Fargo & Company upped their target price on shares of PTC Therapeutics from $106.00 to $109.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.25.

Get Our Latest Stock Report on PTC Therapeutics

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.